Rosmantuzumab（Cat No.:I042196）is a monoclonal antibody that targets the receptor HER3 (human epidermal growth factor receptor 3), which is involved in cancer cell growth and survival. HER3 is often overexpressed in various cancers, including breast, ovarian, and non-small cell lung cancer (NSCLC). By binding to HER3, rosmantuzumab aims to block signaling pathways that promote tumor growth and resistance to treatment. It is being studied in clinical trials for its potential to treat solid tumors, particularly those resistant to other therapies, and to improve outcomes by inhibiting key pathways driving cancer progression.
